Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8644161 | 0.93 | LTA4H (0.86) | LTA4H | |
| SCHEMBL7140388 | 0.90 | LTA4H (1.00) | LTA4H | |
| SCHEMBL7138681 | 0.90 | LTA4H (0.82) | LTA4H | |
| SCHEMBL5173600 | 0.90 | LTA4H (0.81) | LTA4H | |
| SCHEMBL17842060 | 0.89 | LTA4H (0.80) | LTA4H | |
| SCHEMBL5175537 | 0.89 | LTA4H (0.80) | LTA4H | |
| SCHEMBL7141718 | 0.88 | LTA4H (1.00) | LTA4H | |
| SCHEMBL7141632 | 0.87 | LTA4H (0.81) | LTA4H | |
| SCHEMBL7137454 | 0.87 | LTA4H (0.77) | LTA4H | |
| SCHEMBL5174985 | 0.86 | LTA4H (0.76) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126004-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS | Rogne Bioscience Inc. (US) | 2017-02-08 | — | — | EP | claimed |
| WO-2015153838-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS | ROGNE BIOSCIENCE INC. (US) | 2015-10-08 | — | — | WO | claimed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | claimed |
| WO-2010065491-A2 | METHODS OF TREATING INFLAMMATORY DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| WO-2010056910-A2 | METHODS OF TREATING CARDIOVASCULAR DISORDERS | CAROLUS THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| EP-1670445-A2 | METHODS OF PREVENTING OR TREATING RECURRENCE OF MYOCARDIAL INFARCTION | Decode Genetics EHF. (IS) | 2006-06-21 | — | — | EP | claimed |
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005027886-A2 | METHODS OF PREVENTING OR TREATING RECURRENCE OF MYOCARDIAL INFARCTION | DECODE GENETICS EHF. (IS) | 2005-03-31 | — | — | WO | claimed |
| EP-1221441-A2 | LTA4 Hydrolase inhibitors | G.D. SEARLE & CO. (US) | 2002-07-10 | — | — | EP | claimed |
| EP-0804427-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | claimed |
| EP-0786992-A2 | LTA 4? HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | claimed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | claimed |
| EP-3755371-A1 | COMBINATION CANCER THERAPY WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGEN | Abexxa Biologics, Inc. (US) | 2020-12-30 | — | — | EP | disclosed |
| WO-2019165307-A1 | COMBINATION CANCER THERAPY WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX COMPRISING NON-CLASSICAL HLA-I AND NEOANTIGEN | ABEXXA BIOLOGICS, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| EP-3126004-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISORDERS | Rogne Bioscience Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-5585492-A | USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES WHICH ARE MEDIATED BY LTB4 PRODUCTION, SUCH AS PSORIASIS, ULCERATIVE COLITIS, IRRITABLE BOWEL DISEASE AND ASTHMA | G. D. SEARLE & CO. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996010999-A2 | LTA4 HYDROLASE INHIBITOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1996011192-A1 | LTA4 HYDROLASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-04-18 | — | — | WO | disclosed |